Natreon’s Sensoril® Ashwagandha Improves Strength Training Adaptations and Recovery in Recently Published Clinical Trial
NEW BRUNSWICK, NJ, December 17, 2018 – Natreon, a leader in Ayurvedic ingredient research and innovation, announced its latest results in the recently published S.T.A.R. (Strength Training Adaptations and Recovery) trial with its clinically studied Sensoril® ashwagandha. Sensoril® is a patented ashwagandha extract supported by more than 10 clinical studies designed to enhance adaptogenic health benefits. Sensoril® is derived from a unique blend of both leaves and roots of the Withania somnifera plant to provide optimal efficacy and bioactive diversity. During this trial, Sensoril® showed significant improvement in both upper and lower-body strength in recreationally active men over a 12-week resistance training and supplementation period.
This U.S. based study, conducted at The Center for Applied Health Sciences, was a 12-week, randomized, parallel-group, placebo-controlled, clinical trial to examine the impact of Sensoril® on strength training adaptations. Subjects were all healthy males between the ages of 18–45 years who were recreationally active, training no more than 2–3 days/week. Subjects were randomized to either receive Sensoril® 500 mg/day, or a placebo. Subjects in the Sensoril® group significantly improved their squat strength by 90%, an increase in leg strength of more than 9 kg, compared to the placebo. There was also a 60% improvement upper body strength (as assessed by the bench press) by more than 4 kg. Sensoril® was also found to significantly improve Perceived Recovery by 14% compared to the baseline while the placebo group showed a significant increase in muscle soreness by more than 40%. Continue Reading